Undeniably, AI is set to revolutionize parts of the market access value chain. But be reassured – there is a future for Market Access professionals.
Manufacturers don’t use fast-track reimbursement in Europe. Although this seems like an oversight, there are six reasons explaining why it is not happening.
A strategic market access consultant won’t create a strategy for you but can help a great deal in optimal decision making and saving money down the road. Here are 5 reasons why you need one.
Some initial market access decisions, made during a unique healthcare crisis, hint at lasting changes for pharmaceutical market access.
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
What is Value-Based Pricing? It’s pricing based on value! Or is it? Let us try to define what it is once and for all.
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
The event that made people pay attention to how prescription drugs are being priced
